Forward P/E Multiple: bluebird bio, Inc (BLUE)

Official company branding of bluebirdbio.com (BLUE)

A liquidity crisis and the costly launch of platforms are forcing bluebird bio, Inc. (BLUE) to pivot its sales model. Currently, bluebird bio, Inc. (BLUE) is focusing on the expansion of Lyfgenia to capture the DNA pharma market. The company's projected P/E multiple reflects demand dynamics, where 0.00 represents the most recent metric value. This confirms its status as a gene therapy pioneer developing methods for the complete cure of hereditary blood pathologies.

BLUE - bluebird bio Market Cap to Projected Earnings over the range 07/04/2022 - 06/07/2025

bluebird bio (BLUE) - metric breakdowns and financial figures

- company stock exchange capitalization indicators:
Fundamental valuation:Bluebird Bio
Brand item of bluebirdbio.com

The assessment of operational business resilience is based on the ratio of market capitalization to expected net income, allowing investors to determine the premium paid for future growth. For bluebird bio, Inc. (BLUE), this logic reflects market confidence in the monetization of an expanded gene therapy portfolio and the expansion of clinics, which is clearly visualized by the company's forward P/E metric.

Competing companies

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Biotechnology Inc (NAUT)|Projected Price to Earnings MGX|DTIL (Precision BioSciences) - Market Cap to Future Earnings Ratio|Future Price to Earnings Generation Bio Corp (GBIO)|Boundless Bio - Price to Future Earnings Ratio|Future Price to Earnings Exicure, Inc. XCUR|Future Price to Earnings Multiple IMNN|PHIO - Future Price to Earnings|Market Cap to Projected Earnings Mustang Bio Inc MBIO|RNAZ: Forward P/E Multiple|Price to Future Earnings Ratio BNGO|APDN (Applied DNA Sciences Inc) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple